NEJM â Collection Updates for Prostate Disease

CLINICAL IMPLICATIONS OF BASIC RESEARCH: A Seminal Finding for Prostate Cancer?

Jiaoti Huang, M.D., Ph.D., and Owen N. Witte, M.D. — Thu, 14Â JanÂ 2010 00:00:00 -05:00

The traditional view is that prostate cancer arises from mature luminal cells of the prostate gland.1 Studies of other cancers, however, have implicated more primitive stem and progenitor cells as...

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 1-2010 â A 75-Year-Old Man with Hypertension, Hyperglycemia, and Edema

Thu, 14Â JanÂ 2010 00:00:00 -05:00

Dr. Jennifer L. Lyons (Medicine): A 75-year-old man was admitted to this hospital because of the recent onset of hypertension, hyperglycemia, and edema.

The patient had been in his usual state...

CLINICAL IMPLICATIONS OF BASIC RESEARCH: The Index Lesion and the Origin of Prostate Cancer

Hashim Uddin Ahmed, M.R.C.S., B.M., B.Ch. — Thu, 22Â OctÂ 2009 00:00:00 -05:00

Prostate cancer is a perplexing type of malignant disease. Its long natural history means that men who receive the diagnosis in their 50s or 60s do not necessarily require treatment....

ORIGINAL ARTICLE: Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

Thu, 20Â AugÂ 2009 00:00:00 -05:00

Background: Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human...

EDITORIAL: Androgen Deprivation in Prostate Cancer â Step by Step

Peter Albertsen, M.D., M.S. — Thu, 11Â JunÂ 2009 00:00:00 -05:00

Clinicians and researchers have debated the relative efficacy and timing of androgen deprivation since 1941, when Charles B. Huggins and Clarence V. Hodges reported that androgen deprivation reduced testosterone levels...

ORIGINAL ARTICLE: Duration of Androgen Suppression in the Treatment of Prostate Cancer

Thu, 11Â JunÂ 2009 00:00:00 -05:00

Background: The combination of radiotherapy plus long-term medical suppression of androgens (â¥2 years) improves overall survival in patients with locally advanced prostate cancer. We compared the use of radiotherapy plus...

PERSPECTIVE: Screening for Prostate Cancer

Thu, 26Â MarÂ 2009 00:00:00 -05:00

In two large randomized trials, researchers examined the effect of annual prostate-specificâantigen (PSA) screening on the rate of death from prostate cancer and found that it was small and was...

EDITORIAL: Screening for Prostate Cancer â The Controversy That Refuses to Die

Michael J. Barry, M.D. — Thu, 26Â MarÂ 2009 00:00:00 -05:00

In the United States, most men over the age of 50 years have had a prostate-specificâantigen (PSA) test,1 despite the absence of evidence from large, randomized trials of a net...

ORIGINAL ARTICLE: Screening and Prostate-Cancer Mortality in a Randomized European Study

Thu, 26Â MarÂ 2009 00:00:00 -05:00

Background: The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specificâantigen (PSA) testing on death rates from...

ORIGINAL ARTICLE: Mortality Results from a Randomized Prostate-Cancer Screening Trial

Thu, 26Â MarÂ 2009 00:00:00 -05:00

Background: The effect of screening with prostate-specificâantigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the...

CLINICAL DECISIONS: Management of Prostate Cancer â Polling Results

Robert S. Schwartz, M.D. — Thu, 15Â JanÂ 2009 00:00:00 -05:00

In early December, we presented the case of a 63-year-old man with a rising prostate-specific antigen (PSA) level in Clinical Decisions,1 an interactive feature designed to assess how readers would...

BOOK REVIEW:

Thu, 15Â JanÂ 2009 00:00:00 -05:00

The appropriate treatment of prostate cancer continues to challenge researchers and clinicians. During the past decade, intensive screening for prostate-specific antigen has resulted in a dramatic rise in the number...

ORIGINAL ARTICLE: Alfuzosin and Symptoms of Chronic ProstatitisâChronic Pelvic Pain Syndrome

Thu, 18Â DecÂ 2008 00:00:00 -05:00

Background: In men with chronic prostatitisâchronic pelvic pain syndrome, treatment with alpha-adrenergic receptor blockers early in the course of the disorder has been reported to be effective in some, but...

CLINICAL DECISIONS: Management of Prostate Cancer

Thu, 11Â DecÂ 2008 00:00:00 -05:00

A 63-year-old man who has been under your care for the past 3 years undergoes an annual check-up. He believes he is in excellent health, and he has no medical...

PERSPECTIVE: Screening for Prostate Cancer among Men 75 Years of Age or Older

Thu, 11Â DecÂ 2008 00:00:00 -05:00

Prostate-cancer screening with the prostate-specific antigen (PSA) test remains one of the most controversial issues in modern medicine. The U.S. Preventive Services Task Force (USPSTF), an independent group of experts...

BOOK REVIEW:

Thu, 04Â DecÂ 2008 00:00:00 -05:00

Approximately 10% of men are affected by the enigmatic condition known as chronic prostatitisâchronic pelvic pain syndrome. Traditionally, the prostate has been implicated, but emerging evidence implicates other organs and...

BOOK REVIEW:

Thu, 09Â OctÂ 2008 00:00:00 -05:00

Disorders that cause genitourinary pain and inflammation are common and can be life-altering because of their effects on the quality of life. In the preface of this book, editor Jeannette...

BOOK REVIEW:

Thu, 14Â AugÂ 2008 00:00:00 -05:00

More than 218,000 new cases of prostate cancer are diagnosed every year in the United States. Great improvements in diagnosis and treatment have been made over the past two decades,...

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 15-2008 â A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer

Michael J. Barry, M.D., Donald S. Kaufman, M.D., and Chin-Lee Wu, M.D., Ph.D. — Thu, 15Â MayÂ 2008 00:00:00 -05:00

Dr. Donald S. Kaufman: A 55-year-old man was referred to this hospital for management of prostate cancer. He had been well until approximately 1 year earlier, when he noted the...

ORIGINAL ARTICLE: Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors

Thu, 20Â MarÂ 2008 00:00:00 -05:00

Background: We sought to identify determinants of health-related quality of life after primary treatment of prostate cancer and to measure the effects of such determinants on satisfaction with the outcome...

EDITORIAL: Complexities of Prostate-Cancer Risk

Edward P. Gelmann, M.D. — Thu, 28Â FebÂ 2008 00:00:00 -05:00

As men age, prostate epithelial cells are subjected to substantial stresses, and these stresses can damage DNA, thereby causing cellular transformation. The aging prostate gland acquires numerous foci of cancer...

ORIGINAL ARTICLE: Cumulative Association of Five Genetic Variants with Prostate Cancer

Thu, 28Â FebÂ 2008 00:00:00 -05:00

Background: Single-nucleotide polymorphisms (SNPs) in five chromosomal regions â three at 8q24 and one each at 17q12 and 17q24.3 â have been associated with prostate cancer. Each SNP has only...

CLINICAL PRACTICE: Localized Prostate Cancer

Thu, 27Â DecÂ 2007 00:00:00 -05:00

A 68-year-old man presents with newly diagnosed prostate cancer. Over the past 3 years, his serum prostate-specific antigen (PSA) level has been slowly and steadily increasing (from 4.0 ng per...

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 18-2007 â A 54-Year-Old Man with Early-Stage Prostate Cancer

Thu, 14Â JunÂ 2007 00:00:00 -05:00

A 54-year-old man was seen in consultation at the Multidisciplinary Genitourinary Clinic of the Cancer Center of this hospital because of a recent diagnosis of prostate cancer.

Approximately 3 years earlier,...

CLINICAL PRACTICE: Chronic Prostatitis and the Chronic Pelvic Pain Syndrome

Anthony J. Schaeffer, M.D. — Thu, 19Â OctÂ 2006 00:00:00 -05:00

A 38-year-old man reports pelvic pain, dysuria, and urinary urgency for the past 4 weeks. He has had several similar episodes over the past 2 years; urine cultures were not...

CLINICAL THERAPEUTICS: External-Beam Radiotherapy for Localized Prostate Cancer

Thomas M. Pisansky, M.D. — Thu, 12Â OctÂ 2006 00:00:00 -05:00

A 69-year-old man undergoes a follow-up evaluation after testing showed an elevated serum prostate-specific antigen (PSA) level. One year previously, he had requested serum PSA testing after receiving counseling regarding...

IMAGES IN CLINICAL MEDICINE: Subacute Urinary Retention

Sameer Kassem, M.D. and Gideon Friedman, M.D. — Thu, 09Â FebÂ 2006 00:00:00 -05:00

An 88-year-old man with benign prostate hypertrophy and ischemic heart disease who had undergone an anterior peritoneal resection due to adenocarcinoma of the rectum presented with a three-month history of...

EDITORIAL: Proven and Unproven Therapy for Benign Prostatic Hyperplasia

Robert S. DiPaola, M.D., and Ronald A. Morton, M.D. — Thu, 09Â FebÂ 2006 00:00:00 -05:00

The Food and Drug Administration (FDA) is the regulatory body charged with assessing the basic and clinical science underlying the introduction of new drugs into clinical practice and evaluating the...

ORIGINAL ARTICLE: Saw Palmetto for Benign Prostatic Hyperplasia

Thu, 09Â FebÂ 2006 00:00:00 -05:00

Background: Saw palmetto is used by over 2 million men in the United States for the treatment of benign prostatic hyperplasia and is commonly recommended as an alternative to drugs...

ORIGINAL ARTICLE: Autoantibody Signatures in Prostate Cancer

Thu, 22Â SepÂ 2005 00:00:00 -05:00

Background: New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer.

Methods: With a phage-display library derived from prostate-cancer tissue, we developed and used phage protein microarrays...

ORIGINAL ARTICLE: Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

Thu, 12Â MayÂ 2005 00:00:00 -05:00

Background: In 2002, we reported the initial results of a trial comparing radical prostatectomy with watchful waiting in the management of early prostate cancer. After three more years of follow-up,...

ORIGINAL ARTICLE: Risk of Fracture after Androgen Deprivation for Prostate Cancer

Thu, 13Â JanÂ 2005 00:00:00 -05:00

Background: The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk...

ORIGINAL ARTICLE: Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Thu, 07Â OctÂ 2004 00:00:00 -05:00

Background: Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate...

ORIGINAL ARTICLE: Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Thu, 07Â OctÂ 2004 00:00:00 -05:00

Background: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with...

PERSPECTIVE: Mechanisms of Androgen-Refractory Prostate Cancer

Jose D. Debes, M.D., and Donald J. Tindall, Ph.D. — Thu, 07Â OctÂ 2004 00:00:00 -05:00

Prostate cancer is the second-leading cause of cancer-related death among men and the seventh most common cause of death in the United States overall. Most prostate cancers are androgen-dependent, meaning...

EDITORIAL: Progress toward Identifying Aggressive Prostate Cancer

Mario Eisenberger, M.D., and Alan Partin M.D, Ph.D. — Thu, 08Â JulÂ 2004 00:00:00 -05:00

Measurement of prostate-specific antigen (PSA) has profoundly affected virtually all clinical aspects of prostate cancer. A sharp increase in both the incidence of age-adjusted prostate cancer (about 100 percent) and...

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 21-2004 â A 63-Year-Old Man with Metastatic Prostate Carcinoma Refractory to Hormone Therapy

Thu, 08Â JulÂ 2004 00:00:00 -05:00

A 63-year-old man was evaluated in the clinic because of metastatic prostate cancer that was no longer responding to hormone therapy.

The patient had been well until eight years before he...

ORIGINAL ARTICLE: Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy

Thu, 08Â JulÂ 2004 00:00:00 -05:00

Background: We evaluated whether men at risk for death from prostate cancer after radical prostatectomy can be identified using information available at diagnosis.

Methods: We studied 1095 men with localized prostate...

EDITORIAL: Prostate Cancers in Men with Low PSA Levels â Must We Find Them?

H. Ballentine Carter, M.D. — Thu, 27Â MayÂ 2004 00:00:00 -05:00

Prostate cancer is the second leading cause of death from cancer among men in the United States. In the era before prostate-specific antigen (PSA) screening, most prostate cancers were identified...

ORIGINAL ARTICLE: Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level â¤4.0 ng per Milliliter

Thu, 27Â MayÂ 2004 00:00:00 -05:00

Background: The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial...

EDITORIAL: Medical Management of Benign Prostatic Hyperplasia â Are Two Drugs Better Than One?

E. Darracott Vaughan, Jr., M.D. — Thu, 18Â DecÂ 2003 00:00:00 -05:00

The prostate is a complex organ composed of epithelial cells and fibromuscular stroma. Benign prostatic hyperplasia is a true hyperplastic process, with an increase in the number of cells arising...

ORIGINAL ARTICLE: The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

Thu, 18Â DecÂ 2003 00:00:00 -05:00

Background: Benign prostatic hyperplasia is commonly treated with alpha-adrenergicâreceptor antagonists (alpha-blockers) or 5Î±-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is...

EDITORIAL: Verification Bias and the Prostate-Specific Antigen Test â Is There a Case for a Lower Threshold for Biopsy?

Fritz H. SchrÃ¶der, M.D., Ph.D., and Ries Kranse, Ph.D. — Thu, 24Â JulÂ 2003 00:00:00 -05:00

Verification bias can influence the interpretation of the most important screening test for prostate cancer, measurement of prostate-specific antigen (PSA). Such bias arises when the presence or absence of prostate...

REVIEW ARTICLE: Prostate Cancer

Thu, 24Â JulÂ 2003 00:00:00 -05:00

Prostate cancer is a leading cause of illness and death among men in the United States and Western Europe. Autopsy series have revealed small prostatic carcinomas in up to 29...

ORIGINAL ARTICLE: Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen

Thu, 24Â JulÂ 2003 00:00:00 -05:00

Background: The sensitivity and specificity of a screening test are biased when disease status is not verified in all subjects and when the likelihood of confirmation depends on the test...

EDITORIAL: The Prevention of Prostate Cancer â The Dilemma Continues

Peter T. Scardino, M.D. — Thu, 17Â JulÂ 2003 00:00:00 -05:00

Prostate cancer is the most common non-skin cancer in the United States, the second leading cause of death from cancer among U.S. men, and the seventh leading cause of death...

PERSPECTIVE: A Big Study Yields Big Questions

Abigail Zuger, M.D. — Thu, 17Â JulÂ 2003 00:00:00 -05:00

It seems that death and taxes are not the only sure things in life anymore. Now, all adults in late middle age must also confront a complex individualized calculation of...

PERSPECTIVE: New Horizons in Oncologic Imaging

Dow-Mu Koh, F.R.C.R., Gary J.R. Cook, M.D., and Janet E. Husband, F.R.C.R. — Thu, 19Â JunÂ 2003 00:00:00 -05:00

In recent years, the adoption of a multidisciplinary approach to the care of patients with cancer has changed the landscape of oncologic practice. Using this model, surgeons, oncologists, radiologists, pathologists,...

IMAGES IN CLINICAL MEDICINE: Calcified Left Ventricular Aneurysm

Byron K. Lee, M.D. and J. Edwin Atwood, M.D. — Thu, 06Â MarÂ 2003 00:00:00 -05:00

A 70-year-old man with a history of a myocardial infarction, hormone-refractory metastatic prostate cancer, and chronic renal insufficiency presented with chest pain. Electrocardiography revealed atrial fibrillation and ST-segment elevation in...

PERSPECTIVE: Herbal Medicines â What's in the Bottle?

Thu, 19Â DecÂ 2002 00:00:00 -05:00

We are in the midst of a public health experiment that much of academic medicine has failed to acknowledge until recently. In spite of the greatest health and longevity in...

EDITORIAL: Surgery and the Reduction of Mortality from Prostate Cancer

Thu, 12Â SepÂ 2002 00:00:00 -05:00

More than ever, it is important to establish definitively whether aggressive management of localized prostate cancer reduces the rate of death due to prostate cancer, because this tumor is now...

ORIGINAL ARTICLE: Quality of Life after Radical Prostatectomy or Watchful Waiting

Thu, 12Â SepÂ 2002 00:00:00 -05:00

Background: We evaluated symptoms and self-assessments of quality of life in men with localized prostate cancer who participated in a randomized comparison between radical prostatectomy and watchful waiting.

Methods: Between 1989...

ORIGINAL ARTICLE: A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer

Thu, 12Â SepÂ 2002 00:00:00 -05:00

Background: Radical prostatectomy is widely used in the treatment of early prostate cancer. The possible survival benefit of this treatment, however, is unclear. We conducted a randomized trial to address...

SPECIAL ARTICLE: Variations in Morbidity after Radical Prostatectomy

Thu, 11Â AprÂ 2002 00:00:00 -05:00

Background: Recent studies of surgery for cancer have demonstrated variations in outcomes among hospitals and among surgeons. We sought to examine variations in morbidity after radical prostatectomy for prostate cancer.

Methods:...

EDITORIAL: Bone Loss Accompanying Medical Therapies

Thu, 27Â SepÂ 2001 00:00:00 -05:00

In this issue of the Journal, two groups of investigators report that the treatment of a primary medical condition resulted in accelerated bone loss.12 In one study, by Smith et...

ORIGINAL ARTICLE: Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer

Thu, 27Â SepÂ 2001 00:00:00 -05:00

Background: Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of the prevention...

CLINICAL PRACTICE: Prostate-SpecificâAntigen Testing for Early Diagnosis of Prostate Cancer

Michael J. Barry, M.D. — Thu, 03Â MayÂ 2001 00:00:00 -05:00

A 65-year-old man with no risk factors for prostate cancer except his age has a normal digital rectal examination. Should a prostate-specificâantigen (PSA) test be ordered?...

EDITORIAL: Early Androgen Deprivation for Prostate Cancer?

Thu, 09Â DecÂ 1999 00:00:00 -05:00

The dependence of the growth of prostate cancer on androgens is well documented. Androgen ablation triggers a cascade of biologic events that ends in irreversible damage to the DNA of...

EDITORIAL: Early Androgen Deprivation for Prostate Cancer?

Thu, 09Â DecÂ 1999 00:00:00 -05:00

The dependence of the growth of prostate cancer on androgens is well documented. Androgen ablation triggers a cascade of biologic events that ends in irreversible damage to the DNA of...

ORIGINAL ARTICLE: Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer

Thu, 09Â DecÂ 1999 00:00:00 -05:00

Background: Because the optimal timing of the institution of antiandrogen therapy for prostate cancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after...

ORIGINAL ARTICLE: Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer

Thu, 09Â DecÂ 1999 00:00:00 -05:00

ORIGINAL ARTICLE: Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

Thu, 08Â OctÂ 1998 00:00:00 -05:00

Background: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to...

ORIGINAL ARTICLE: Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate Cancer

Thu, 17Â SepÂ 1998 00:00:00 -05:00

Background: Herbal mixtures are popular alternatives to demonstrated therapies. PC-SPES, a commercially available combination of eight herbs, is used as a nonestrogenic treatment for cancer of the prostate. Since other...

EDITORIAL: Finasteride to Prevent Morbidity from Benign Prostatic Hyperplasia

Thu, 26Â FebÂ 1998 00:00:00 -05:00

Finasteride, a 5Î±-reductase inhibitor that slows the conversion of testosterone to dihydrotestosterone, is now a proven treatment for men who wish to reduce the genitourinary symptoms or the risk of...

ORIGINAL ARTICLE: The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia

Thu, 26Â FebÂ 1998 00:00:00 -05:00

Background: Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of...

EDITORIAL: Prostate Cancer â The Therapeutic Challenge of Locally Advanced Disease

Thu, 31Â JulÂ 1997 00:00:00 -05:00

The treatment of localized prostate cancer is a matter of considerable controversy. For decades experts vigorously debated the relative merits of radical prostatectomy and external-beam radiotherapy. During those years the...

ORIGINAL ARTICLE: Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

Thu, 31Â JulÂ 1997 00:00:00 -05:00

Background: We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients with locally advanced...

EDITORIAL: Contentious Screening Decisions â Does the Choice Matter?

Thu, 24Â AprÂ 1997 00:00:00 -05:00

Artists often understand us better than we understand ourselves. A cartoon in the March 26 edition of the Philadelphia Daily News shows a physician who, after exhaustively reviewing the literature,...

EDITORIAL: Treatment of Benign Prostatic Hyperplasia

Thu, 22Â AugÂ 1996 00:00:00 -05:00

Medications to treat benign prostatic hyperplasia fall into two main categories: Î±1-adrenergicâantagonist drugs, which relax smooth muscle in the prostate, and drugs that inhibit 5Î±-reductase, which shrink the prostate by...

ORIGINAL ARTICLE: The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

Thu, 22Â AugÂ 1996 00:00:00 -05:00

Background: Men with benign prostatic hyperplasia can be treated with Î±1-adrenergicâantagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5Î±-reductase and therefore reduce tissue androgen concentrations. However,...

EDITORIAL: Age-Specific Reference Ranges for Serum PSA

Thu, 01Â AugÂ 1996 00:00:00 -05:00

The measurement of prostate-specific antigen (PSA) in serum is the most useful tool available today for the diagnosis of early, curable adenocarcinoma of the prostate.1 This issue of the Journal...

EDITORIAL: Age-Specific Reference Ranges for Serum PSA

Thu, 01Â AugÂ 1996 00:00:00 -05:00

The measurement of prostate-specific antigen (PSA) in serum is the most useful tool available today for the diagnosis of early, curable adenocarcinoma of the prostate.1 This issue of the Journal...

ORIGINAL ARTICLE: Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men

Thu, 01Â AugÂ 1996 00:00:00 -05:00

Background: The detection of prostate cancer by screening for prostate-specific antigen (PSA) in serum is improved when age-specific reference ranges are used, but these ranges have been derived from white...

ORIGINAL ARTICLE: Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men

Thu, 01Â AugÂ 1996 00:00:00 -05:00

NEJM â Collection Updates for Prostate Disease

CLINICAL IMPLICATIONS OF BASIC RESEARCH: A Seminal Finding for Prostate Cancer?

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 1-2010 â A 75-Year-Old Man with Hypertension, Hyperglycemia, and Edema

CLINICAL IMPLICATIONS OF BASIC RESEARCH: The Index Lesion and the Origin of Prostate Cancer

ORIGINAL ARTICLE: Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

EDITORIAL: Androgen Deprivation in Prostate Cancer â Step by Step

ORIGINAL ARTICLE: Duration of Androgen Suppression in the Treatment of Prostate Cancer

PERSPECTIVE: Screening for Prostate Cancer

EDITORIAL: Screening for Prostate Cancer â The Controversy That Refuses to Die

ORIGINAL ARTICLE: Screening and Prostate-Cancer Mortality in a Randomized European Study

ORIGINAL ARTICLE: Mortality Results from a Randomized Prostate-Cancer Screening Trial

CLINICAL DECISIONS: Management of Prostate Cancer â Polling Results

BOOK REVIEW:

ORIGINAL ARTICLE: Alfuzosin and Symptoms of Chronic ProstatitisâChronic Pelvic Pain Syndrome

CLINICAL DECISIONS: Management of Prostate Cancer

PERSPECTIVE: Screening for Prostate Cancer among Men 75 Years of Age or Older

BOOK REVIEW:

BOOK REVIEW:

BOOK REVIEW:

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 15-2008 â A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer

ORIGINAL ARTICLE: Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors

EDITORIAL: Complexities of Prostate-Cancer Risk

ORIGINAL ARTICLE: Cumulative Association of Five Genetic Variants with Prostate Cancer

CLINICAL PRACTICE: Localized Prostate Cancer

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 18-2007 â A 54-Year-Old Man with Early-Stage Prostate Cancer

CLINICAL PRACTICE: Chronic Prostatitis and the Chronic Pelvic Pain Syndrome

CLINICAL THERAPEUTICS: External-Beam Radiotherapy for Localized Prostate Cancer

IMAGES IN CLINICAL MEDICINE: Subacute Urinary Retention

EDITORIAL: Proven and Unproven Therapy for Benign Prostatic Hyperplasia

ORIGINAL ARTICLE: Saw Palmetto for Benign Prostatic Hyperplasia

ORIGINAL ARTICLE: Autoantibody Signatures in Prostate Cancer

ORIGINAL ARTICLE: Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

ORIGINAL ARTICLE: Risk of Fracture after Androgen Deprivation for Prostate Cancer

ORIGINAL ARTICLE: Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

ORIGINAL ARTICLE: Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

PERSPECTIVE: Mechanisms of Androgen-Refractory Prostate Cancer

EDITORIAL: Progress toward Identifying Aggressive Prostate Cancer

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 21-2004 â A 63-Year-Old Man with Metastatic Prostate Carcinoma Refractory to Hormone Therapy

ORIGINAL ARTICLE: Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy

EDITORIAL: Prostate Cancers in Men with Low PSA Levels â Must We Find Them?

ORIGINAL ARTICLE: Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level â¤4.0 ng per Milliliter

EDITORIAL: Medical Management of Benign Prostatic Hyperplasia â Are Two Drugs Better Than One?

ORIGINAL ARTICLE: The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

EDITORIAL: Verification Bias and the Prostate-Specific Antigen Test â Is There a Case for a Lower Threshold for Biopsy?

REVIEW ARTICLE: Prostate Cancer

ORIGINAL ARTICLE: Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen

EDITORIAL: The Prevention of Prostate Cancer â The Dilemma Continues

PERSPECTIVE: A Big Study Yields Big Questions

PERSPECTIVE: New Horizons in Oncologic Imaging

IMAGES IN CLINICAL MEDICINE: Calcified Left Ventricular Aneurysm

PERSPECTIVE: Herbal Medicines â What's in the Bottle?

EDITORIAL: Surgery and the Reduction of Mortality from Prostate Cancer

ORIGINAL ARTICLE: Quality of Life after Radical Prostatectomy or Watchful Waiting

ORIGINAL ARTICLE: A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer

SPECIAL ARTICLE: Variations in Morbidity after Radical Prostatectomy

EDITORIAL: Bone Loss Accompanying Medical Therapies

ORIGINAL ARTICLE: Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer

CLINICAL PRACTICE: Prostate-SpecificâAntigen Testing for Early Diagnosis of Prostate Cancer

EDITORIAL: Early Androgen Deprivation for Prostate Cancer?

EDITORIAL: Early Androgen Deprivation for Prostate Cancer?

ORIGINAL ARTICLE: Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer

ORIGINAL ARTICLE: Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer

ORIGINAL ARTICLE: Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

ORIGINAL ARTICLE: Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate Cancer

EDITORIAL: Finasteride to Prevent Morbidity from Benign Prostatic Hyperplasia

ORIGINAL ARTICLE: The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia

EDITORIAL: Prostate Cancer â The Therapeutic Challenge of Locally Advanced Disease

ORIGINAL ARTICLE: Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

EDITORIAL: Contentious Screening Decisions â Does the Choice Matter?

EDITORIAL: Treatment of Benign Prostatic Hyperplasia

ORIGINAL ARTICLE: The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

EDITORIAL: Age-Specific Reference Ranges for Serum PSA

EDITORIAL: Age-Specific Reference Ranges for Serum PSA

ORIGINAL ARTICLE: Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men

ORIGINAL ARTICLE: Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men

NEJM â Collection Updates for Prostate Disease

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 1-2010 â A 75-Year-Old Man with Hypertension, Hyperglycemia, and Edema

EDITORIAL: Androgen Deprivation in Prostate Cancer â Step by Step

EDITORIAL: Screening for Prostate Cancer â The Controversy That Refuses to Die

CLINICAL DECISIONS: Management of Prostate Cancer â Polling Results

ORIGINAL ARTICLE: Alfuzosin and Symptoms of Chronic ProstatitisâChronic Pelvic Pain Syndrome

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 15-2008 â A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 18-2007 â A 54-Year-Old Man with Early-Stage Prostate Cancer

CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL: Case 21-2004 â A 63-Year-Old Man with Metastatic Prostate Carcinoma Refractory to Hormone Therapy

EDITORIAL: Prostate Cancers in Men with Low PSA Levels â Must We Find Them?

ORIGINAL ARTICLE: Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level â¤4.0 ng per Milliliter

EDITORIAL: Medical Management of Benign Prostatic Hyperplasia â Are Two Drugs Better Than One?

EDITORIAL: Verification Bias and the Prostate-Specific Antigen Test â Is There a Case for a Lower Threshold for Biopsy?

EDITORIAL: The Prevention of Prostate Cancer â The Dilemma Continues

PERSPECTIVE: Herbal Medicines â What's in the Bottle?

CLINICAL PRACTICE: Prostate-SpecificâAntigen Testing for Early Diagnosis of Prostate Cancer

EDITORIAL: Prostate Cancer â The Therapeutic Challenge of Locally Advanced Disease

EDITORIAL: Contentious Screening Decisions â Does the Choice Matter?